Download PDF

Facts, Views & Vision in ObGyn

Publication date: 2013-01-01
Pages: 106 - 115
Publisher: Institute for Fertility Technology, Department of Obstetrics and Gynaecology, Genk

Author:

Göker, M
Devoogdt, Nele ; Van De Putte, Gregg ; Schobbens, JC ; Vlasselaer, Jos ; Van den Broecke, R ; de Jonge, ETM

Keywords:

Science & Technology, Life Sciences & Biomedicine, Obstetrics & Gynecology, Breast cancer, lymphoedema, axillary lymph node dissection, definition, incidence, prevalence

Abstract:

AIM: Breast cancer-related lymphoedema (BCRL) is a disabling complication developing after breast cancer treatment in a proportion of patients. Its impact on quality of life becomes more substantial as survival after breast cancer diagnosis increases. The incidence of BCRL following breast cancer treatment varies due to a lack of -uniform definition and measurement criteria. This review aims to determine the prevalence of BCRL following axillary lymph node dissection (ALND) as a benchmark to be used in a risk-benefit medical decision whether to proceed with ALND or not. The risk of leaving unresected non-sentinel metastatic lymph nodes with a presumed inherent risk of local recurrence will be balanced against the risk of BCRL following a potentially unnecessary ALND. METHODS: Pubmed and Embase databases were searched for all publications on BCRL in order to estimate its -incidence and to decide on the most appropriate measurement method to use in clinical practice. RESULTS: 51 articles were identified on BCRL incidence and measurement technique. Most studies measured BCRL based on differences in arm circumference (n = 18) or by self-reported symptoms (n = 18). The weighted average of BCRL incidence following ALND measured by self-report and circumference method was 28% and 16%, respectively. CONCLUSION: The importance of ALND and irradiation as part of the treatment of operable breast carcinoma is well established, but its morbidity is less well documented. We argue self-report as the most appropriate method to -establish a diagnosis of BCRL. Therefore a 28% risk of finding non-sentinel lymph node metastases in a completion ALND will be regarded as the cut-off in a medical decision to proceed with ALND.